Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization

World Journal of Gastroenterology

Volumn 20, Issue 22, 2014, Pages 6995-7004

  Rou, Woo Sun ^a   Lee, Byung Seok ^a   Moon, Hee Seok ^a   Lee, Eaum Seok ^a   Kim, Seok Hyun ^a   Lee, Heon Young ^a  

^a Chungnam National University College of Medicine   (South Korea)

Author keywords

Chemoembolization; Hepatocellular carcinoma; Lipiodol; Recurrence; Survival

Indexed keywords

ALPHA FETOPROTEIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RECURRENT DISEASE; RISK FACTOR; SURVIVAL RATE; TUMOR VOLUME; ADVERSE EFFECTS; CARCINOMA, HEPATOCELLULAR; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY; RISK; STATISTICAL MODEL; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902141061     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i22.6995     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
2. Pinter M, Hucke F, Graziadei I, Vogel W, Maieron A, Königsberg R, Stauber R, Grünberger B, Müller C, Kölblinger C, Peck-Radosavljevic M, Sieghart W. Advancedstage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 2012; 263: 590-599 [PMID: 22438359 DOI: 10.1148/radiol.12111550]
3. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156]
4. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]
5. Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, Lee KU, Chung JW, Park JH, Kim CY. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002; 20: 4459-4465 [PMID: 12431969 DOI: 10.1200/JCO.2002.02.013]
6. Yang MJ, An SY, Moon EJ, Lee MS, Hwang JA, Cheong JY, Won JH, Kim JK, Wang HJ, Cho SW. [Comparison of radiofrequency ablation and transarterial chemoembolization for the treatment of a single hepatocellular carcinoma smaller than 4 cm]. Korean J Hepatol 2009; 15: 474-485 [PMID: 20037266 DOI: 10.3350/kjhep.2009.15.4.474]
7. Tezuka M, Hayashi K, Okada Y, Irie T, Ina H. Therapeutic results of computed-tomography-guided transcatheter arterial chemoembolization for local recurrence of hepatocellular carcinoma after initial transcatheter arterial chemoembolization: the results of 85 recurrent tumors in 35 patients. Dig Dis Sci 2009; 54: 661-669 [PMID: 18649138 DOI: 10.1007/ s10620-008-0388-6]
8. Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S, Shiraha H, Kuwaki K, Hagihara H, Ikeda F, Miyake Y, Takaki A, Yamamoto K. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol 2012; 47: 421-426 [PMID: 22048256 DOI: 10.1007/s00535-011-0492-9]
9. Lee JK, Chung YH, Song BC, Shin JW, Choi WB, Yang SH, Yoon HK, Sung KB, Lee YS, Suh DJ. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol 2002; 17: 52-58 [PMID: 11895553 DOI: 10.1046/ j.1440-1746.2002.02664.x]
10. Jin YJ, Chung YH, Kim JA, Park W, Lee D, Shim JH, Lee D, Kim KM, Lim YS, Lee HC, Lee YS, Kim PN, Sung KB. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. Dig Dis Sci 2013; 58: 1758-1765 [PMID: 23361574 DOI: 10.1007/s10620-013-2562-8]
11. Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, Sone Y, Toyoda H, Shimada S, Takahashi M, Sassa T. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997; 25: 87-92 [PMID: 8985270 DOI: 10.1002/hep.510250116]
12. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]
13. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60 [PMID: 20175033 DOI: 10.1055/s-0030-1247132]
14. Stefanini GF, Amorati P, Biselli M, Mucci F, Celi A, Arienti V, Roversi R, Rossi C, Re G, Gasbarrini G. Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 1995; 75: 2427-2434 [PMID: 7736385 DOI: 10.1002/1097-0142(1995 0515)75:10<2427::AID-CNCR2820751007>3.0.CO;2-J]
15. Murakami T, Ishimaru H, Sakamoto I, Uetani M, Matsuoka Y, Daikoku M, Honda S, Koshiishi T, Fujimoto T. Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol 2007; 30: 696-704 [PMID: 17497071 DOI: 10.1007/s00270-007-9003-z]
16. Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, Takayama T, Kosuge T, Yamasaki S, Sakamoto M, Hirohashi S. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996; 77: 1792-1796 [PMID: 8646676 DOI: 10.1002/(SICI)1097-0142(19960501)77:9<1792::AIDCNCR6> 3.0.CO;2-E]
17. Tezuka M, Hayashi K, Kubota K, Sekine S, Okada Y, Ina H, Irie T. Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. Dig Dis Sci 2007; 52: 783-788 [PMID: 17268830 DOI: 10.1007/s10620-006-9537-y]
18. Park W, Chung YH, Kim JA, Jin YJ, Lee D, Shim JH, Lee D, Kim KM, Lim YS, Lee HC, Lee YS, Kim PN, Sung KB. Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns. Hepatol Res 2013; 43: 1304-1312 [PMID: 23442052 DOI: 10.1111/ hepr.12083]
19. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94: 1747-1752 [PMID: 11920537 DOI: 10.1002/cncr.10407]
20. Jeon SH, Park KS, Kim YH, Shin YS, Kang MK, Jang BK, Chung WJ, Cho KB, Hwang JS. [Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma]. Korean J Gastroenterol 2007; 50: 176-182 [PMID: 17885283]
21. Hsin IF, Hsu CY, Huang HC, Huang YH, Lin HC, Lee RC, Chiang JH, Lee FY, Huo TI, Lee SD. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction. J Clin Gastroenterol 2011; 45: 556-562 [PMID: 21666547 DOI: 10.1097/MCG.0b013e318210ff17]
22. Huang YS, Chiang JH, Wu JC, Chang FY, Lee SD. Risk of hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma: predictive value of the monoethylglycinexylidide test. Am J Gastroenterol 2002; 97: 1223-1227 [PMID: 12014732 DOI: 10.1111/j.1572-0241.2002.05709.x]
23. Matsuo N, Uchida H, Soda S, Ohshima M, Nakano H, Ohishi H, Nagano N, Kitanura I, Nishimura Y, Nishimine K, Yoshioka T. Histopathological study of the resected specimens after Segmental Lp-TAE using Lipiodol mixed with anticancer agent for hepatocellular carcinoma. Anti-tumor effect and influence on non-tumor area. Acta Hepatol Jpn 1990; 31: 1084-1093 [DOI: 10.2957/kanzo.31.1084]
24. Raby N, Karani J, Michell M, Gimson A, Nunnerley H, Williams R. Lipiodol enhanced CT scanning in assessment of hepatocellular carcinoma. Clin Radiol 1989; 40: 480-485 [PMID: 2551562 DOI: 10.1016/S0009-9260(89)80254-5]
25. Matsuo N, Uchida H, Sakaguchi H, Nishimine K, Nishimura Y, Hirohashi S, Ohishi H. Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on lipiodol accumulation patterns and histopathologic findings. Semin Oncol 1997; 24: S6-61-S6-S6-61-70 [PMID: 9151919]
26. Kwan SW, Fidelman N, Ma E, Kerlan RK, Yao FY. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 2012; 18: 727-736 [PMID: 22344899 DOI: 10.1002/lt.23413]
27. Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, Kojima J, Ishikawa O, Ohigashi H, Furukawa H. A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987; 60: 1194-1203 [PMID: 2441837 DOI: 10.1002/1097-01 42(19870915)60:6<1194::AID-CNCR2820600607>3.0.CO;2-T]
28. Kanematsu T, Furuta T, Takenaka K, Matsumata T, Yoshida Y, Nishizaki T, Hasuo K, Sugimachi K. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology 1989; 10: 98-102 [PMID: 2544499 DOI: 10.1002/hep.1840100119]
29. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, Hasegawa H, Hirohashi S. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987; 163: 345-351 [PMID: 3031724]
30. Nishimine K, Uchida H, Matsuo N, Sakaguchi H, Hirohashi S, Nishimura Y, Guo Q, Ohishi H, Nagano N, Yoshioka T. Segmental transarterial chemoembolization with Lipiodol mixed with anticancer drugs for nonresectable hepatocellular carcinoma: follow-up CT and therapeutic results. Cancer Chemother Pharmacol 1994; 33 Suppl: S60-S68 [PMID: 7511069 DOI: 10.1007/BF00686670]
31. Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004; 41: 864-880 [PMID: 15519663 DOI: 10.1016/j.jhep.2004.09.006]
32. Arora AS, de Groen PC, Croall DE, Emori Y, Gores GJ. Hepatocellular carcinoma cells resist necrosis during anoxia by preventing phospholipase-mediated calpain activation. J Cell Physiol 1996; 167: 434-442 [PMID: 8655597 DOI: 10.1002 /(SICI)1097-4652(199606)167:3<434::AID-JCP7>3.0.CO;2-Q]
33. Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, Giampalma E, Renzulli M, Bolondi L. Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". J Hepatol 2012; 57: 1258-1267 [PMID: 22871502 DOI: 10.1016/j.jhep.2012.07.025]
34. Shirabe K, Kajiyama K, Harimoto N, Masumoto H, Fukuya T, Ooya M, Maehara Y. Prognosis of hepatocellular carcinoma accompanied by microscopic portal vein invasion. World J Gastroenterol 2009; 15: 2632-2637 [PMID: 19496194 DOI: 10.3748/wjg.15.2632]